Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PGRN – RIKEN: Genetic Determinants of Clinical Cardiovascular Events in Patients Receiving Statins

ABSTRACT: PGRN – RIKEN: Genetic Determinants of Clinical Cardiovascular Events in Patients Receiving Statins

PROVIDER: PRJNA290826 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

PGRN-RIKEN:Genetic Determinants of Cardiovascular Events while on Statins

Project description:<p>Coronary heart disease (CHD) is an important public health problem in developed countries. Statins are effective in the prevention and treatment of CHD; nevertheless, many patients receiving statins still suffer cardiovascular events (CV) such as heart attack. Identifying genetic variants responsible for differential clinical responses to statins will not only allow individual patients at high residual risk to be targeted for additional therapies, but also will define new biologic pathways contributing to statin response, and thus new targets for future therapies. Accordingly, the goal of this study is to identify genetic variants associated with clinical CV in patients receiving statins.</p> <p>Subjects identified for study are of European descent and include 1718 subjects with CV while on statins (cases) and 4172 subjects without CV while on statins (controls). Key research resources utilized in this effort include VanderbiltD's BioVU DNA databank and associated Synthetic Derivative database of clinical information, and software tools developed to identify drugs and clinical events using Electronic Health Record-derived structured and unstructured ("free text") data. Most cases and controls identified include three data types: ICD-9 codes, medication regimens, and medical test results. Genotyping, using IlluminaD's Infinium HumanOmniExpressExome BeadChip (OmniExpressExome), was performed by the RIKEN Integrative Medical Sciences Center (IMS) and supported by the Pharmacogenomics Research Network (PGRN)-RIKEN IMS Global Alliance.</p>

| phs000963 | dbGaP

PGRN-RIKEN Mayo Breast Cancer

Project description:PGRN-RIKEN Mayo Breast Cancer

| PRJNA75545 | ENA

PGRN-RIKEN Mayo-NSABP Prevention Study

Project description:PGRN-RIKEN Mayo-NSABP Prevention Study

| PRJNA75693 | ENA

PGRN-RIKEN: Rate Control Therapy in Patients with Atrial Fibrillation

Project description:PGRN-RIKEN: Rate Control Therapy in Patients with Atrial Fibrillation

| PRJNA80275 | ENA

Homo sapiens

Project description:PGRN – RIKEN: Genetic Determinants of Clinical Cardiovascular Events in Patients Receiving Statins

| PRJNA290827 | ENA

PGRN-RIKEN:Genome-Wide Association Study of Drug-Induced Long-QT Syndrome

Project description:PGRN-RIKEN:Genome-Wide Association Study of Drug-Induced Long-QT Syndrome

| PRJNA75677 | ENA

PGRN-RIKEN-CALGB 80303 - Genome-wide Pharmacogenomic Study of Gemcitabine and Bevacizumab in Advanced Pancreatic Cancer

Project description:PGRN-RIKEN-CALGB 80303 - Genome-wide Pharmacogenomic Study of Gemcitabine and Bevacizumab in Advanced Pancreatic Cancer

| PRJNA75653 | ENA

PGRN-RIKEN-CALGB 40101 - Genome-wide Pharmacogenomic Study of Cyclophosphamide, Doxorubicin and Paclitaxel in Breast Cancer

Project description:PGRN-RIKEN-CALGB 40101 - Genome-wide Pharmacogenomic Study of Cyclophosphamide, Doxorubicin and Paclitaxel in Breast Cancer

| PRJNA262702 | ENA

Systematic expression profiling of the mouse transcriptome using RIKEN cDNA microarrays

Project description:Expression profiling of multiple mouse tissues against 57931 RIKEN cDNAs Keywords: dual color nucleotide, tissue comparison

2005-12-20 | GSE3098 | GEO

Statins affect gene expression in pancreatic cancer

Project description:The statin family of cholesterol-lowering drugs was shown to influence the risk of multiple types of cancers. However, the anti-tumor effects of statins in pancreatic cancer and their efficacy differs among the individual statins, are not currently well-defined. Thus, the aim of the present study was to identify the biological pathways affected by individual statins in human pancreatic cancer. The study was performed on human pancreatic cancer cell linesMiaPaCa-2 and PANC-1, exposed to three statins (Lovastatin, Fluvastatin and Simvastatin). mRNA-seq were performed (Sequenced with PE150, and 20M reads were generated.)

2020-04-30 | GSE149566 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data